Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11.

2.

Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection.

Price MA, Rida W, Kilembe W, Karita E, Inambao M, Ruzagira E, Kamali A, Sanders EJ, Anzala O, Hunter E, Allen S, Edward VA, Wall KM, Tang J, Fast PE, Kaleebu P, Lakhi S, Mutua G, Bekker LG, Abu-Baker G, Tichacek A, Chetty P, Latka MH, Maenetje P, Makkan H, Kibengo F, Priddy F, Gilmour J.

J Infect Dis. 2019 Jul 2;220(3):432-441. doi: 10.1093/infdis/jiz127.

3.

Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda.

Abaasa A, Nash S, Mayanja Y, Price M, Fast PE, Kamali A, Kaleebu P, Todd J.

Vaccine. 2019 Apr 3;37(15):2065-2072. doi: 10.1016/j.vaccine.2019.02.072. Epub 2019 Mar 8.

4.

Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa.

Powers KA, Price MA, Karita E, Kamali A, Kilembe W, Allen S, Hunter E, Bekker LG, Lakhi S, Inambao M, Anzala O, Latka MH, Fast PE, Gilmour J, Sanders EJ.

PLoS One. 2018 Apr 3;13(4):e0192785. doi: 10.1371/journal.pone.0192785. eCollection 2018.

5.

Differences in acute retroviral syndrome by HIV-1 subtype in a multicentre cohort study in Africa.

Sanders EJ, Price MA, Karita E, Kamali A, Kilembe W, Bekker LG, Lakhi S, Inambao M, Anzala O, Fast PE, Gilmour J, Powers KA.

AIDS. 2017 Nov 28;31(18):2541-2546. doi: 10.1097/QAD.0000000000001659.

6.

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.

Mutua G, Farah B, Langat R, Indangasi J, Ogola S, Onsembe B, Kopycinski JT, Hayes P, Borthwick NJ, Ashraf A, Dally L, Barin B, Tillander A, Gilmour J, De Bont J, Crook A, Hannaman D, Cox JH, Anzala O, Fast PE, Reilly M, Chinyenze K, Jaoko W, Hanke T, Hiv-Core 004 Study Group T.

Mol Ther Methods Clin Dev. 2016 Aug 31;3:16061. doi: 10.1038/mtm.2016.61. eCollection 2016.

7.

A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Adler SP, Manganello AM, Lee R, McVoy MA, Nixon DE, Plotkin S, Mocarski E, Cox JH, Fast PE, Nesterenko PA, Murray SE, Hill AB, Kemble G.

J Infect Dis. 2016 Nov 1;214(9):1341-1348. Epub 2016 Aug 11.

8.

Status of vaccine research and development of vaccines for HIV-1.

Safrit JT, Fast PE, Gieber L, Kuipers H, Dean HJ, Koff WC.

Vaccine. 2016 Jun 3;34(26):2921-2925. doi: 10.1016/j.vaccine.2016.02.074. Epub 2016 Mar 15.

9.

Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates.

Abaasa A, Asiki G, Price MA, Ruzagira E, Kibengo F, Bahemuka U, Fast PE, Kamali A.

Vaccine. 2016 Apr 4;34(15):1778-85. doi: 10.1016/j.vaccine.2016.02.048. Epub 2016 Mar 2.

10.

An influenza vaccine pill-can we swallow it?

Fast PE, Cox JH.

Lancet Infect Dis. 2015 Sep;15(9):992-993. doi: 10.1016/S1473-3099(15)00252-2. No abstract available.

PMID:
26333316
11.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

12.

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, Karita E, Hayes P, Kopycinski J, Dally L, Hannaman D, Egan MA, Eldridge JH, Syvertsen K, Lehrman J, Rasmussen B, Gilmour J, Cox JH, Fast PE, Schmidt C.

PLoS One. 2015 Aug 7;10(8):e0134287. doi: 10.1371/journal.pone.0134287. eCollection 2015.

13.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium.

Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.

14.

Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa.

Schmidt C, Jaoko W, Omosa-Manyonyi G, Kaleebu P, Mpendo J, Nanvubya A, Karita E, Bayingana R, Bekker LG, Chomba E, Kilembe W, Nchabeleng M, Nyombayire J, Stevens G, Chetty P, Lehrman J, Cox J, Allen S, Dally L, Smith C, Fast PE.

Hum Vaccin Immunother. 2014;10(3):714-23. Epub 2013 Dec 27.

15.

WHO's new guidelines for antiretroviral treatment.

Fast PE, Price MA, Rida WN, Kamali A, Karita E; International AIDS Vaccine Initiative (IAVI) African Early Infection Research Group.

Lancet. 2013 Nov 30;382(9907):1778-9. doi: 10.1016/S0140-6736(13)62539-8. No abstract available.

PMID:
24290585
16.

Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.

Amornkul PN, Karita E, Kamali A, Rida WN, Sanders EJ, Lakhi S, Price MA, Kilembe W, Cormier E, Anzala O, Latka MH, Bekker LG, Allen SA, Gilmour J, Fast PE; IAVI Africa HIV Prevention Partnership.

AIDS. 2013 Nov 13;27(17):2775-86. doi: 10.1097/QAD.0000000000000012.

17.

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D, Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M, Gazzard B, Fast PE, Cox JH, Laufer D.

Clin Vaccine Immunol. 2013 Mar;20(3):397-408. doi: 10.1128/CVI.00637-12. Epub 2013 Jan 23.

18.

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.

Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan VD, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS, Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE.

Hum Vaccin Immunother. 2012 May;8(5):630-8. doi: 10.4161/hv.19454. Epub 2012 May 1.

PMID:
22634443
19.

HIV vaccines: current status worldwide and in Africa.

Fast PE, Kaleebu P.

AIDS. 2010 Oct;24 Suppl 4:S50-60. doi: 10.1097/01.aids.0000390707.58512.5e.

PMID:
21042053
20.

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC.

J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13.

21.

Recent trends in clinical trials of vaccines to prevent HIV/AIDS.

Fast PE.

Curr Opin HIV AIDS. 2006 Jul;1(4):267-71. doi: 10.1097/01.COH.0000232340.77790.7a.

PMID:
19372820
22.

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.

Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, Fast PE, Conlon C, Rowland-Jones S, McMichael AJ, Hanke T.

Vaccine. 2006 Jan 23;24(4):417-25. Epub 2005 Aug 24.

PMID:
16176847
23.

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.

King JC Jr, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, Newman F, Belshe RB, Kovacs A, Deville JG, Jelonek M; HIV Influenza Study Group.

Pediatr Infect Dis J. 2001 Dec;20(12):1124-31.

PMID:
11740317
24.

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.

Longini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast PE, Belshe RB.

Vaccine. 2000 Mar 17;18(18):1902-9.

PMID:
10699339
25.

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.

King JC Jr, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith WE, Lambert JS, Belshe RB.

J Infect Dis. 2000 Feb;181(2):725-8.

PMID:
10669363
26.

Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial.

Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A.

J Clin Microbiol. 2000 Feb;38(2):839-45.

27.

Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women.

Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, Wara DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J.

J Infect Dis. 1999 Oct;180(4):1080-8.

PMID:
10479134
28.

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE.

J Infect Dis. 1998 Feb;177(2):310-9.

PMID:
9466516
29.

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE.

Ann Intern Med. 1996 Aug 15;125(4):270-9.

PMID:
8678389
30.

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.

Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R.

AIDS Res Hum Retroviruses. 1996 May 20;12(8):683-93.

PMID:
8744579
31.

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE.

J Infect Dis. 1996 Feb;173(2):330-9.

PMID:
8568293
32.

Clinical considerations in vaccine trials with special reference to candidate HIV vaccines.

Fast PE, Sawyer LA, Wescott SL.

Pharm Biotechnol. 1995;6:97-134. Review. No abstract available.

PMID:
7551256
33.

Efficacy trials of AIDS vaccines: how science can inform ethics.

Fast PE, Mathieson BJ, Schultz AM.

Curr Opin Immunol. 1994 Oct;6(5):691-7. Review. No abstract available.

PMID:
7826523
34.

Conference on advances in AIDS vaccine development--1993. Report of Perinatal Intervention Working Group.

McNamara JG, Rogers M, Goldenthal K, Jackson JB, Rossi P, Fenton T, Fast PE.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S161-4. No abstract available.

PMID:
7865292
35.

HIV vaccine trials: some design issues including sample size calculation.

Dixon DO, Rida WN, Fast PE, Hoth DF.

J Acquir Immune Defic Syndr. 1993 May;6(5):485-96.

PMID:
8483112
36.

Human trials of experimental AIDS vaccines.

Fast PE, Walker MC.

AIDS. 1993;7 Suppl 1:S147-59. Review. No abstract available.

PMID:
8363779
37.

Summary of the Working Group on Perinatal Intervention.

Mofenson LM, Wright PF, Fast PE.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1435-8. No abstract available.

PMID:
1466976
38.

Orally induced adjuvant-like arthritis in the rat.

Gray JE, Larsen ER, Fast PE, Hamilton RD.

Toxicol Pathol. 1985;13(4):266-75.

PMID:
2422721
39.

Effects of treatment with immunomodulatory drugs on thymus and spleen lymphocyte subpopulations and serum corticosterone levels.

Fast PE, Hatfield CA, Franz CL, Adams EG, Licht NJ, Merritt MV.

Immunopharmacology. 1982 Dec;5(2):135-55.

PMID:
6761307
40.

Renal lesions in MRL mice.

Kolaja GJ, Fast PE.

Vet Pathol. 1982 Nov;19(6):663-8.

PMID:
6216646
41.

Membrane fluidity and cholesterol in thymus and spleen cells from mice treated with immunomodulatory drugs.

Merritt MV, Licht NJ, Hatfield CA, Fast PE.

Immunopharmacology. 1982 Oct;5(1):49-64.

PMID:
6290419
42.

Recovery of lymphocyte function after radiation therapy for cancer in relationship to prognosis.

Stratton JA, Fast PE, Weintraub I.

J Clin Lab Immunol. 1982 Feb;7(2):147-53.

PMID:
7069785

Supplemental Content

Support Center